Neutral
●
PRNewsWire
●
6 months ago
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock Journal HENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people th...